文献速递头颈部肿瘤放疗放疗物理与技术

头颈癌多种IMRT技术的临床结局:倾向评分加权分析

Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer: A Propensity Score-Weighted Analysis.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-06-27

ART-ORL前瞻性比较研究纳入166例鼻咽癌或口咽/口腔鳞癌患者,采用倾向评分逆概率加权调整非随机偏倚,比较螺旋TomoTherapy与容积旋转调强(RapidArc)的临床结局。18个月局部区域控制率和癌症特异生存率TomoTherapy组更优,急性唾液腺障碍更少,但无进展生存和总生存无显著差异。

要点

  • 18个月局部区域控制率TomoTherapy组83.3%优于RapidArc组72.7%(P=.025)。
  • 癌症特异生存率TomoTherapy组97.2%优于RapidArc组85.5%(P=.014)。
  • TomoTherapy急性唾液腺障碍更少(P=.012),RapidArc治疗后唾液功能下降更差(P=.012)。

核心结论

  • TomoTherapy较RapidArc获得更好的局部区域控制和癌症特异生存,且唾液腺障碍更少。
  • 无进展生存和总生存两组间无显著差异。
  • 结果需在随机试验中进一步验证。

研究设计与样本

  • ART-ORL(NCT02024035)为14个中心参与的前瞻性比较研究,因设备可及性无法随机化。
  • 纳入2010年2月至2012年2月间鼻咽癌(表皮样或未分化)或口咽/口腔表皮样癌(T1-T4,M0,N0-N3)患者。
  • 采用倾向评分逆概率治疗加权调整非随机化偏倚,分析纳入166例患者。

主要发现

  • 加权调整后18个月局部区域控制率TomoTherapy组83.3%(95%CI 72.5%-90.2%)vs RapidArc组72.7%(95%CI 62.1%-80.8%),P=.025。
  • 癌症特异生存率TomoTherapy组97.2%(95%CI 89.3%-99.3%)vs RapidArc组85.5%(95%CI 75.8%-91.5%),P=.014。
  • 无进展生存和总生存无显著差异。
  • TomoTherapy组急性唾液腺障碍更少(P=.012),RapidArc组治疗后唾液功能下降更差(P=.012)。

关键数值与推荐

  • 18个月局部区域控制率TomoTherapy组83.3%(95%CI 72.5%-90.2%)vs RapidArc组72.7%(95%CI 62.1%-80.8%),P=.025。
  • 癌症特异生存率TomoTherapy组97.2%(95%CI 89.3%-99.3%)vs RapidArc组85.5%(95%CI 75.8%-91.5%),P=.014。
  • 急性唾液腺障碍TomoTherapy组更少,P=.012;治疗后唾液功能下降RapidArc组更差,P=.012。

临床怎么用

  • 在头颈癌IMRT技术选择中,TomoTherapy可能带来更好的局部区域控制和癌症特异生存,并减少唾液腺障碍。
  • 无进展生存和总生存无显著差异,技术选择需综合考量。
  • 研究结果支持在随机试验中进一步探索TomoTherapy与RapidArc的疗效差异。

局限性

  • 研究因设备可及性无法随机化,采用倾向评分加权调整潜在偏倚。
  • 仅报告临床结果,经济学评估结果已另文发表。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Advanced Radiotherapy Oto-Rhino-Laryngologie (ART-ORL) study (NCT02024035) was performed to prospectively evaluate the clinical and economic aspects of helical TomoTherapy and volumetric modulated arc therapy (RapidArc, Varian Medical Systems, Palo Alto, CA) for patients with head and neck cancer. METHODS AND MATERIALS: Fourteen centers participated in this prospective comparative study. Randomization was not possible based on the availability of equipment. Patients with epidermoid or undifferentiated nasopharyngeal carcinoma or epidermoid carcinoma of the oropharynx and oral cavity (T1-T4, M0, N0-N3) were included between February 2010 and February 2012. Only the results of the clinical study are presented in this report, as the results of the economic assessment have been published previously. Inverse probability of treatment weighting using the propensity score analysis was undertaken in an effort to adjust for potential bias due to nonrandomization. Locoregional control, cancer-specific survival, and overall survival assessed 18 months after treatment, as well as long-term toxicity and salivary function, were evaluated. RESULTS: The analysis included 166 patients. The following results are given after inverse probability of treatment weighting adjustment. The locoregional control rate at 18 months was significantly better in the TomoTherapy group: 83.3% (95% confidence interval [CI], 72.5%-90.2%) versus 72.7% (95% CI, 62.1%-80.8%) in the RapidArc group (P=.025). The cancer-specific survival rate was better in the TomoTherapy group: 97.2% (95% CI, 89.3%-99.3%) versus 85.5% (95% CI, 75.8%-91.5%) in the RapidArc group (P=.014). No significant difference was shown in progression-free or overall survival. TomoTherapy induced fewer acute salivary disorders (P=.012). Posttreatment salivary function degradation was worse in the RapidArc group (P=.012). CONCLUSIONS: TomoTherapy provided better locoregional control and cancer-specific survival than RapidArc treatment, with fewer salivary disorders. No significant difference was shown in progression-free and overall survival. These results should be explored in a randomized trial.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Bibault JE, Dussart S, Pommier P, et al. Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer: A Propensity Score-Weighted Analysis. Int J Radiat Oncol Biol Phys. 2017. PMID: 28864403. doi:10.1016/j.ijrobp.2017.06.2456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。